Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.verified

TARS

Price:

$54.04

Market Cap:

$2.07B

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceutical...[Read more]

Industry

Biotechnology

IPO Date

2020-10-16

Stock Exchange

NASDAQ

Ticker

TARS

The Current Ratio as of December 2024 (TTM) for Tarsus Pharmaceuticals, Inc. (TARS) is 5.42

According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.42. This represents a change of -20.85% compared to the average of 6.85 of the last 4 quarters.

Tarsus Pharmaceuticals, Inc. (TARS) Historical Current Ratio (quarterly & annually)

How has TARS Current Ratio performed in the past?

The mean historical Current Ratio of Tarsus Pharmaceuticals, Inc. over the last ten years is 25.45. The current 5.42 Current Ratio has changed 2.03% with respect to the historical average. Over the past ten years (40 quarters), TARS's Current Ratio was at its highest in in the December 2019 quarter at 70.85. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Quarterly (TTM)
Annual

Average

25.45

Median

14.97

Minimum

6.93

Maximum

70.85

Tarsus Pharmaceuticals, Inc. (TARS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 432.23%

Maximum Annual Current Ratio = 70.85

Minimum Annual Increase = -55.29%

Minimum Annual Current Ratio = 6.93

Quarterly (TTM)
Annual
YearCurrent RatioChange
20236.93-52.53%
202214.61-4.71%
202115.33-51.61%
202031.68-55.29%
201970.85432.23%

Tarsus Pharmaceuticals, Inc. (TARS) Average Current Ratio

How has TARS Current Ratio performed in the past?

The current Current Ratio of Tarsus Pharmaceuticals, Inc. (TARS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

12.29

5-year avg

27.88

10-year avg

25.45

Tarsus Pharmaceuticals, Inc. (TARS) Current Ratio vs. Peers

How is TARS’s Current Ratio compared to its peers?

Tarsus Pharmaceuticals, Inc.’s Current Ratio is less than LianBio (10.06), less than Aldeyra Therapeutics, Inc. (6.80), greater than Travere Therapeutics, Inc. (1.71), greater than Eton Pharmaceuticals, Inc. (1.51), less than Connect Biopharma Holdings Limited (12.04), less than Acumen Pharmaceuticals, Inc. (10.43), less than Nuvation Bio Inc. (9.57), less than Eledon Pharmaceuticals, Inc. (6.53), greater than Opthea Limited (2.94), less than Centessa Pharmaceuticals plc (21.52), less than Nuvalent, Inc. (23.07), greater than Genfit S.A. (3.74), less than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Werewolf Therapeutics, Inc. (10.10), less than Ikena Oncology, Inc. (15.32), greater than Stoke Therapeutics, Inc. (5.09), less than PepGen Inc. (8.47), less than Tyra Biosciences, Inc. (29.55), less than Entrada Therapeutics, Inc. (6.59), less than Pharvaris N.V. (19.08), less than Rallybio Corporation (9.55),

Build a custom stock screener for Tarsus Pharmaceuticals, Inc. (TARS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tarsus Pharmaceuticals, Inc. (TARS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Tarsus Pharmaceuticals, Inc.'s Current Ratio?

How is the Current Ratio calculated for Tarsus Pharmaceuticals, Inc. (TARS)?

What is the highest Current Ratio for Tarsus Pharmaceuticals, Inc. (TARS)?

What is the 3-year average Current Ratio for Tarsus Pharmaceuticals, Inc. (TARS)?

What is the 5-year average Current Ratio for Tarsus Pharmaceuticals, Inc. (TARS)?

How does the current Current Ratio for Tarsus Pharmaceuticals, Inc. (TARS) compare to its historical average?